Discover how Chroma is expanding our impact.

Boston, MA, September 27, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the addition of innovative biotech business leader Michael A. Kelly to its Board of Directors. “Michael brings decades of strategic finance and business operations experience to Chroma and builds on the deep expertise of our current board and leadership team. We are excited to welcome him as we pursue the promise of epigenetic editing for patients,” said Catherine Stehman-Breen, M.D., Chief Executive Officer of Chroma. Mr. Kelly is the Founder and President of Sentry Hill Partners, LLC, a global…

Boston, MA., September 21, 2023 — Chroma Medicine, Inc. (Chroma), a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced it was named to the Endpoints 11 2023 list of the most promising biotechs by Endpoints News. This annual award celebrates companies with leading-edge science that are pioneering the development of new medicines. Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma is rapidly advancing a new class of therapeutics that harness epigenetics, nature’s innate mechanism for gene regulation, to achieve unparalleled control of gene expression without cutting, nicking, or altering the DNA sequence. After securing…

Boston, MA, September 20, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented positive preclinical data demonstrating the potential of its epigenetic editors to produce efficacious, specific, and durable silencing of the hepatitis B virus (HBV) during the HBV International Meeting 2023, held September 19-23 in Kobe, Japan. Chronic hepatitis B is incurable, increases the risk of developing liver cirrhosis and hepatocellular cancer, and impacts nearly 300 million people worldwide, accounting for more than 800,000 deaths per year. Antiviral therapy can suppress viral replication, but requires lifelong dosing and few patients achieve…